Aggregated price index
Aggregated price index with volume information
Summary:
- Medical Specialties stocks up 0.4% on average while median return up 0.2% in a day
- Medical Specialties stocks up 1.1% on average while median return up 1.1% in a week
- Medical Specialties stocks up 1.3% on average while median return up -0.1% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
Click on + to show price series and click on ticker for stock detail page
* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.
* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.
* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.
- 1M winners are : Winners for past month are $PAVMW 105.6%, $PAVMZ 79.0%, $PAVM 57.1%, $VCEL 34.6%, $GNMK 34.2%
- 1M losers are : Losers for past month are $RWLK -27.6%, $CHFS -30.5%, $ATOS -30.6%, $MLSS -31.3%, $CLSN -32.5%
- 1W winners are : Winners for past week are $PAVMW 43.3%, $PAVMZ 29.1%, $SPNE 22.5%, $NEPH 22.1%, $BIOL 21.5%
- 1W losers are : Losers for past week are $RWLK -11.6%, $RVP -12.0%, $MLSS -13.7%, $BLPH -13.8%, $TMDX -23.5%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 20.3%, for the past 3 months is 16.2%
In the past month for a 5 days rolling window, the highest corrrelation is 52.9%, the lowest correlation is 4.4%, the latest correlation is 12.0%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 78.1% between ATRI and ATRS
The lowest correlation is -55.2% between AXGN and BDXB
Stock news
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Dentsply Sirona Inc.Global Credit Research - 09 Apr 2021New York, April 09, 2021 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Dentsply Sirona Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review discussion held on 7 April 2021 in which Moody's reassessed the appropriateness of the r...
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Stryker CorporationGlobal Credit Research - 09 Apr 2021New York, April 09, 2021 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Stryker Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review discussion held on 7 April 2021 in which Moody's reassessed the appropriateness of the rat...
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Edwards Lifesciences CorporationGlobal Credit Research - 09 Apr 2021New York, April 09, 2021 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Edwards Lifesciences Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review discussion held on 7 April 2021 in which Moody's reassessed the ...
Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) seeking accelerated approval for tisotumab vedotin. This BLA requests FDA approval of tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target ...
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:
NEW YORK, NY / ACCESSWIRE / April 9, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.
HRC vs. BLFS: Which Stock Is the Better Value Option?
Tenax shares rose after the company reported progress in a Phase 2 study of levosimendan to treat pulmonary hypertension and heart failure.